Skip to main
EVH

Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health (EVH) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 38%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Evolent Health is poised for success in the rapidly growing value-based care market, with its specialty-focused approach and diverse offerings driving strong revenue growth. The company's strong contract protections and improved visibility on revenue increases from payer partners provide a solid foundation for growth and margin stability. While risks related to customer concentration and increasing cancer prevalence could impact performance, Evolent's differentiated and scalable business model sets it apart as a leader in the industry.

Bears say

Evolent Health is facing potential risks and challenges that could impact its ability to effectively manage costs and achieve profitability in its value-based care contracts. While its recent financial performance has been solid, its high level of debt, coupled with healthcare cost inflation and potential implementation delays, could hinder its future growth and lead to lower earnings and reduced valuation multiples. Additionally, while the company boasts a diverse portfolio of services and clients, increased competition in the healthcare industry could put pressure on Evolent's market share and pricing power, limiting its ability to generate sustainable revenue and margins. Thus, caution is warranted when considering an investment in Evolent Health's stock.

Evolent Health (EVH) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 38% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Evolent Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Evolent Health (EVH) Forecast

Analysts have given Evolent Health (EVH) a Buy based on their latest research and market trends.

According to 13 analysts, Evolent Health (EVH) has a Buy consensus rating as of Jun 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Evolent Health (EVH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.